On the other hand, two SGLT-2 inhibitors (SGLT2i), empagliflozin and dapagliflozin, have proven to be beneficial in patients with chronic HF with reduced ejection fraction (HFrEF), with or without type 2 diabetes mellitus (T2DM), in the EMPEROR-Reduced and DAPA-HF studies [5,6]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.